MetaCap

Cabaletta Bio (CABA) vs Compugen (CGEN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Compugen (CGEN) has outperformed Cabaletta Bio (CABA) over the past year, gaining 20.3% versus a loss of 55.0%. Over five years, CGEN leads with a -59.5% price change compared with -91.9% for CABA. Cabaletta Bio is the larger company by market cap ($201.9 million vs $174.3 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CABA-55.00%CGEN+20.26%
+110%+24%-63%
Nov 21, 20251 yearNov 20, 2026
CABA-92.19%CGEN-60.93%
+119%+7%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CABA versus CGEN key metrics
MetricCABACGEN
Share price$0.9361$1.84
Market cap$201.94M$174.29M
1-day change-7.32%-2.13%
YTD return-57.26%+20.26%
1-year return-55.00%+20.26%
5-year return-91.93%-59.47%
P/E ratio (TTM)—4.72
EPS (TTM)$-1.33$0.39
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$72.76M
Revenue growth (YoY)—+161.14%
Net income (latest FY)$-167.86M$35.34M
Gross margin—87.29%
Operating margin—43.05%
Net margin—48.57%
52-week high$4.23$3.24
52-week low$0.93$1.43
Distance from 52-week high-77.87%-43.21%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+1155.21%+160.87%
Average volume5.15M223.56K
Shares outstanding215.72M94.72M
Employees15475
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CGEN has outperformed CABA by 75.3 percentage points over the past year.

About Cabaletta Bio

CABA stock →

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 154 employees

About Compugen

CGEN stock →

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 75 employees

CABA vs CGEN FAQ

Which is bigger, Cabaletta Bio or Compugen?

Cabaletta Bio (CABA) is larger, with a market capitalization of $201.94M compared with $174.29M for Compugen (CGEN).

Which stock has performed better over the past year, CABA or CGEN?

CGEN returned +20.26% over the past 12 months, compared with -55.00% for CABA (price return, excluding dividends). Past performance does not predict future results.

Are Cabaletta Bio and Compugen in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons